𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical trial of benznidazole and an immunopotentiator against Chagas disease in Chile

✍ Scribed by Werner Apt; Arturo Arribada; Fernando Arab; JoséM. Ugarte; Iván Luksic; Claudio Solé

Publisher
Elsevier Science
Year
1986
Tongue
English
Weight
131 KB
Volume
80
Category
Article
ISSN
0035-9203

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of longitudinal data in an Alzh
Analysis of longitudinal data in an Alzheimer's disease clinical trial
✍ Ronald G. Thomas; Julie D. Berg; Mary Sano; Leon Thal 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Evidence of delayed progression is the primary mechanism for demonstrating therapeutic e cacy in clinical trials in Alzheimer's disease. In the major trials of therapeutic treatment of AD, to date, measures based on clinical judgement and cognitive performance, instead of mortality, have been used a

The need for levodopa as an end point of
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol
✍ Dr. Peter LeWitt; David Oakes; Lu Cui 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

## Abstract Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to th

An index of the three core data set pati
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial
✍ T. Pincus; V. Strand; G. Koch; I. Amara; B. Crawford; F. Wolfe; S. Cohen; D. Fel 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 3 views